prostate%20cancer
PROSTATE CANCER

Prostate cancer is the cancer that occurs in the male's prostate.

It is the most common cancer in men >50 years of age.

Signs and symptoms include weak urinary stream, polyuria, nocturia, hematuria, erectile dysfunction, pelvic pain, back pain, chest pain, lower extremity weakness or numbness and loss of bowel or bladder control.

Supportive Therapy

Pharmacological Therapy

  • Mitoxantrone may be used for patients with symptomatic metastatic castration-resistant prostate cancer (CRPC) who have contraindications to Cabazitaxel or Radium-223 therapy
  • Denosumab and bisphosphonates (Eg Alendronate, Pamidronate, Zoledronic acid) may be suggested in patients with metastatic castration-resistant prostate cancer (CRPC) with bone metastasis to help prevent bone fractures, metastases, and other skeletal complications

Radiation Therapy

  • Recommended dose:
    • Non-vertebral metastases: 800 cGy x 10 fractions
    • Widespread bone metastases: Sr-89 or Sm-153 with or without focal external beam radiation therapy (EBRT)

Referral

  • Refer patient and his family to facilities that can provide palliative care services that can assist both the patient and his family while dealing with prostate cancer
  • Referral to pain clinics or palliative care team may also help in the symptomatic management of prostate cancer patients
Editor's Recommendations
Most Read Articles
09 Nov 2017
Treatment with fesoterodine shows efficacy in patients with nocturnal urgency secondary to overactive bladder syndrome and low nocturnal bladder capacity with a mismatch between nocturnal urine production and bladder capacity, reports a recent study.
14 Nov 2017
The 5-year survival rates for human papillomavirus (HPV)-associated cancers vary greatly according to age and race, with Caucasians and younger patients tending to have better survival, according to a recent US study.
01 Nov 2017
High-grade serous carcinomas (HGSCs) of the pelvis, whether associated with serous tubal intra-epithelial carcinoma lesions or not, appear to have shared biologic origin in the distal fallopian tube, according to a recent study.
28 Nov 2017
The use of oral androgen receptor inhibitor enzalutamide may benefit chemotherapy-naïve patients with metastatic castration-resistant prostate cancer and low baseline prostate specific antigen irrespective of disease burden, signifying that targeting the androgen receptor signalling pathway is a therapeutic option in similar patients, suggests a recent study.